Soleno Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Soleno Therapeutics, Inc.
Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
- Drug Delivery
- Diagnostic Equipment & Supplies
- Other Names / Subsidiaries
- Capnia, Inc.
- Essentialis, Inc.